{"id":60412,"date":"2024-02-28T06:47:45","date_gmt":"2024-02-28T06:47:45","guid":{"rendered":"https:\/\/medsname.com\/rasalect\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rasalect","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/rasalect\/","title":{"rendered":"Rasalect"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 R\u0103spuns rapid<\/h3>\n

Rasalect<\/strong> este un rasagiline<\/strong> (1 mg) tablet \u2014 a selective de monoaminoxidaz\u0103 tip B (MAO-B)<\/strong> utilizat pentru tratarea Boala Parkinson<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Unlike selegiline, rasagiline is prime\u0219te,<\/em> metabolised to amphetamine derivatives, so insomnia is much less of a problem. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Important:<\/strong> evita\u021bi combina\u021bia cu majoritatea antidepresivelor (SSRI, SNRI, TCA), opioide precum petidina \u0219i tramadol, \u0219i dextrometorfan \u2014 risc de atunci c\u00e2nd este combinat cu agen\u021bi serotoninergici (SSRI, SNRI, IMAO, tramadol, petidin\u0103, triptane, linezolidul fiind el \u00eensu\u0219i un slab inhibitor MAO). Este esen\u021bial\u0103 revizuirea strict\u0103 a medicamentelor concomitente \u00eenainte de \u00eenceperea tratamentului.<\/em>.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n

What Is Rasalect?<\/h2>\n

Rasalect is an oral tablet containing rasagiline 1 mg<\/strong>. rasagiline is a selective de monoaminoxidaz\u0103 tip B (MAO-B)<\/strong> introdus ini\u021bial ca Azilect<\/strong>. Rasalect is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Rasagiline was developed as a second-generation MAO-B inhibitor specifically to avoid selegiline’s amphetamine metabolites. It has a clean active metabolite (aminoindan) which itself has neuroprotective properties in laboratory models. Rasagiline can be used as monotherapy in early Parkinson disease or as adjunct to levodopa for end-of-dose wearing-off.<\/p>\n

How Does Rasalect (rasagiline) Work?<\/h2>\n

Rasagiline irreversibly inactivates MAO-B in the brain, slowing the breakdown of dopamine. Like selegiline it is selective for MAO-B at therapeutic doses (1 mg\/day) but loses selectivity above 1.5–2 mg\/day. Its main metabolite, aminoindan, has its own potential neuroprotective activity in preclinical models — the basis for the ADAGIO disease-modification trial, which produced suggestive but not conclusive results.<\/p>\n

Compararea inhibitorilor MAO-B<\/h2>\n

Cei trei inhibitori MAO-B utiliza\u021bi \u00een boala Parkinson \u2014 selegilin\u0103, rasagilin\u0103 \u0219i safinamid\u0103 \u2014 au un mecanism comun, dar difer\u0103 semnificativ \u00een ceea ce prive\u0219te metabolitele, dozarea \u0219i pozi\u021bionarea clinic\u0103:<\/p>\n\n\n\n\n\n\n\n\n\n
Caracteristic\u0103<\/th>\nSelegilin\u0103<\/th>\nRasagilin\u0103<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Doza tipic\u0103<\/td>\n5\u201310 mg\/zi<\/td>\n0,5\u20131 mg\/zi<\/td>\n50\u2013100 mg\/zi<\/td>\n<\/tr>\n
Metaboli\u021bi activi<\/td>\nAmfetamin\u0103 + metamfetamin\u0103<\/td>\nAminoindan (non-amfetaminic)<\/td>\nF\u0103r\u0103 metabolit stimulant activ<\/td>\n<\/tr>\n
Efectul glutamat<\/td>\nNu<\/td>\nNu<\/td>\nDa<\/strong> \u2014 modularea canalului de sodiu\/eliber\u0103rii de glutamat<\/td>\n<\/tr>\n
Indica\u021bie<\/td>\nMonoterapie sau adjunct<\/td>\nMonoterapie sau adjunct<\/td>\nDoar adjunct<\/strong> \u2014 pentru PD fluctuant la levodopa<\/td>\n<\/tr>\n
Risc de insomnie<\/td>\nMai ridicat (metaboli\u021bi de amfetamin\u0103)<\/td>\nSc\u0103zut<\/td>\nSc\u0103zut<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Rasalect For?<\/h2>\n

Rasalect is appropriate for adults with Parkinson disease — either as monotherapy in early disease or as adjunct to levodopa in patients with motor fluctuations. Compared with selegiline, rasagiline is preferred when insomnia is a concern. Compared with safinamide, rasagiline is the better monotherapy option (safinamide is licensed only as adjunct).<\/p>\n

Dozare \u0219i administrare<\/h2>\n

Doza standard pentru adul\u021bi este 1 mg o dat\u0103 pe zi<\/strong>, taken in the morning with or without food. There is no need for titration — full effect is reached within 1–2 weeks. Doses above 1 mg\/day are generally avoided as MAO-B selectivity is lost. In moderate hepatic impairment reduce to 0.5 mg\/day; in severe hepatic impairment avoid.<\/p>\n\n\n\n\n\n\n\n
Popula\u021bie<\/th>\nDoza<\/th>\n<\/tr>\n<\/thead>\n
Standard adult<\/td>\n1 mg once daily, morning<\/td>\n<\/tr>\n
Disfunc\u021bie hepatic\u0103 u\u0219oar\u0103<\/td>\n0.5 mg once daily<\/td>\n<\/tr>\n
Moderate-severe hepatic impairment<\/td>\nEvita\u021bi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\u26a0 Tiramina \u0219i \u201cefectul br\u00e2nzei\u201d<\/strong> La doze standard selective MAO-B, restric\u021bia dietetic\u0103 la tiramin\u0103 este \u00een general prime\u0219te,<\/em> necesar\u0103. Cu toate acestea, selectivitatea MAO-B depinde de doz\u0103 \u2014 selegilina peste 10 mg\/zi, rasagilina peste 1 mg\/zi \u0219i safinamida peste 100 mg\/zi pierd selectivitatea \u0219i inhib\u0103 \u0219i MAO-A periferic. La aceste doze, alimentele bogate \u00een tiramin\u0103 (br\u00e2nzeturi \u00eemb\u0103tr\u00e2nite, carne afumat\u0103, fasole larg\u0103, soia fermentat\u0103, bere la halb\u0103) pot declan\u0219a o criz\u0103 hipertensiv\u0103. Respecta\u021bi dozele prescrise pentru a evita acest risc.<\/div>\n

Efecte Secundare Comune<\/h2>\n

Headache (the most common — usually transient), arthralgia, dyspepsia, depression, postural hypotension, flu-like symptoms. Less common: hallucinations, insomnia (much less than selegiline), weight loss, falls. With levodopa: increased dyskinesia.<\/p>\n

\u26a0 Sindromul serotoninergic \u2014 interac\u021biuni periculoase<\/strong> Asocierea unui inhibitor MAO-B cu medicamente serotoninergice poate provoca atunci c\u00e2nd este combinat cu agen\u021bi serotoninergici (SSRI, SNRI, IMAO, tramadol, petidin\u0103, triptane, linezolidul fiind el \u00eensu\u0219i un slab inhibitor MAO). Este esen\u021bial\u0103 revizuirea strict\u0103 a medicamentelor concomitente \u00eenainte de \u00eenceperea tratamentului.<\/em>: agita\u021bie, transpira\u021bii, tremur, hiperreflexie, febr\u0103, diaree, \u00een cazuri severe convulsii \u0219i deces. Evita\u021bi:<\/strong> SSRI (fluoxetin\u0103, sertralin\u0103, paroxetin\u0103, citalopram, escitalopram), SNRI (venlafaxin\u0103, duloxetin\u0103), triciclice (amitriptilin\u0103, imipramin\u0103), petidin\u0103 (meperidin\u0103), tramadol, dextrometorfan, metadon\u0103, iarba Sf\u00e2ntului Ioan, MDMA. Perioade de \u00eentrerupere:<\/strong> \u00eentrerupe\u021bi fluoxetina cu 5 s\u0103pt\u0103m\u00e2ni \u00eenainte de a \u00eencepe inhibitorul MAO-B; \u00eentrerupe\u021bi alte SSRI\/SNRI cu cel pu\u021bin 2 s\u0103pt\u0103m\u00e2ni \u00eenainte; nu \u00eencepe\u021bi fluoxetina \u00een decurs de 2 s\u0103pt\u0103m\u00e2ni de la \u00eentreruperea inhibitorului MAO-B.<\/div>\n

Interac\u021biuni Medicamentoase \u0219i Alimentare<\/h2>\n